Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancer
稳定核 p27kip1 作为子宫内膜癌的治疗靶点
基本信息
- 批准号:9094005
- 负责人:
- 金额:$ 7.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-06-13 至 2019-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffectAtypical Endometrial HyperplasiasBindingBiological AvailabilityBiological MarkersBiopsyCancer BiologyCell CycleCell Cycle ProteinsCell Cycle RegulationCell NucleusCell ProliferationCellsCessation of lifeChemicalsComplexCrystallizationCyclin-Dependent Kinase InhibitorDataDevelopmentDiseaseEndometrialEndometrial CarcinomaEndometriumEpithelialEpithelial Cell ProliferationEpithelial CellsEstrogensEventG1 ArrestG1 PhaseGenerationsGrowthGrowth InhibitorsGynecologicHealthHormonal CarcinogenesisHormonesHumanImage AnalysisImmunocompromised HostIn VitroInjection of therapeutic agentKnowledgeLeadLearningLeftLibrariesMalignant - descriptorMalignant NeoplasmsMediatingMicroscopyMolecularMolecular TargetMusNeoplasm MetastasisNuclearOncogenesOutcomePathogenesisPathway interactionsPatientsPharmaceutical PreparationsProgesteroneProteasome InhibitorProteinsPublishingRegulationReportingRoleSystemTestingTherapeuticTherapeutic AgentsTherapeutic InterventionTherapeutic UsesTissuesToxic effectTransforming Growth Factor betaTumor Suppressor ProteinsTumor VolumeUbiquitinX-Ray CrystallographyXenograft procedurebiophysical analysiscancer cellcancer therapycarcinogenesiscellular imagingchemical groupin vivoinhibitor/antagonistinsightknock-downmigrationmouse modelmulticatalytic endopeptidase complexnew therapeutic targetnovelnovel strategiesnovel therapeutic interventionpharmacophorepreventprotein degradationscaffoldsmall moleculespatiotemporaltherapeutic targettraffickingtreatment strategytumorubiquitin ligaseubiquitin-protein ligase
项目摘要
DESCRIPTION (provided by applicant): As loss of cell cycle regulation is a hallmark of carcinogenesis, identifying novel therapeutic targets aimed at restoring growth control is an important approach to cancer therapy. Endometrial cancer (ECA) is the most common gynecologic malignancy in the US with 49,470 new cases and over 8,190 deaths estimated for 2013. The major objectives of this proposal address mechanisms involved in the pathogenesis of estrogen (E2)- induced Type I ECA (85% of ECAs) and a new potential therapy for this disease that involves inhibiting degradation of the tumor suppressor, p27kip1 (p27), a key cell cycle protein that arrests cell proliferation. We reported that E2 induces ubiquitin-mediated degradation of nuclear p27 by its specific E3 ligase, SCF- Skp2/Cks1, in endometrial epithelial (EECs) and ECA cells with increased cell proliferation. Conversely, progesterone (Pg; a therapy for low grade ECA) as well as TGF-ß, increase p27 in the nucleus and inhibit cell proliferation by preventing p27 degradation. Therefore, we provide compelling evidence that p27 is a key target for growth regulation in the endometrium and in endometrial carcinogenesis. We have identified novel small molecule inhibitors of Skp2/Cks1 (Skp2E3LIs) that only increase nuclear p27, which is critical since cytoplasmic p27 mediated migration/metastasis. Furthermore, Skp2E3LIs block both E2-induced degradation of nuclear p27 and proliferation in vitro in ECA cells and {in vivo in mouse EECs}. Importantly, Skp2E3LIs have the potential to be a major therapeutic advancement over current general proteasome inhibitors that indiscriminately block protein degradation including oncogenes. Whereas Skp2/Cks1 causes p27 degradation, the E3 ligase APC/Cdh1 targets Cks1/Skp2 for destruction leaving p27 intact. Interestingly, we show that E2 decreases Cdh1and thereby increases Skp2/Cks1 for p27 degradation whereas Pg and TGF-ß increase Cdh1 to increase nuclear p27. Therefore, p27 degradation can be inhibited both, by increasing Cdh1 or by blocking Skp2. As such, we will test two main hypotheses: 1. that the Cdh1-Skp2/Cks1-p27axis is important in cell cycle dysregulation by the ubiquitin proteasome system (UPS); 2. that Skp2E3LIs have significant translational value for the treatment of ECA. We propose to: 1. Use E2, Pg, and TGF-ß as molecular switches to learn how Cdh1 is controlled to affect p27 levels. 2. Show that co-localization of p27 and Cdh1 in human biopsy tissue is a biomarker for positive outcomes of Pg therapy. {3. Perform co-crystallization/NMR structural analysis of Skp2-Cks1-Skp2E3LI complexes for chemically optimizing current lead compounds to define the role of p27 in ECA in vitro and in vivo.} 4. Quantify the effects of Skp2E3LIs on intracellular [nuclear] trafficking of p27 Skp2, and Cks1 together with cell cycle analysis by single cell imaging microscopy. 5. Test Skp2E3LIs for their efficacy in blocking the growth of human ECA tumors in mouse models. As the degradation of nuclear p27 occurs in numerous cancers, our studies should impact the cancer biology field by providing mechanistic insights into the role of the UPS in cancer and the use of Skp2E3LIs as a novel approach to cancer therapy.
描述(由申请人提供):由于细胞周期调节的丧失是致癌的标志,因此识别旨在恢复生长控制的新型治疗靶点是癌症治疗的重要方法。子宫内膜癌(ECA)是美国最常见的妇科恶性肿瘤,2013年估计有49,470例新发病例和超过8,190例死亡。该提案的主要目标是解决雌激素(E2)诱导的I型ECA(85%的ECA)的发病机制,以及这种疾病的新的潜在治疗方法,包括抑制肿瘤抑制因子p27 kip 1(p27)的降解,这是一种阻止细胞增殖的关键细胞周期蛋白。我们报道了E2通过其特异性E3连接酶SCF-Skp 2/Cks 1诱导子宫内膜上皮细胞(EECs)和ECA细胞中泛素介导的核p27降解,并增加细胞增殖。相反,孕酮(Pg;低级别ECA的治疗)以及TGF-β,增加细胞核中的p27并通过防止p27降解来抑制细胞增殖。因此,我们提供了令人信服的证据表明,p27是子宫内膜生长调节和子宫内膜癌发生的关键目标。我们已经发现了新型Skp 2/Cks 1小分子抑制剂(Skp 2 E3 LIs),它只增加细胞核p27,这一点至关重要,因为细胞质p27介导迁移/转移。此外,Skp 2 E3 LIs阻断E2诱导的ECA细胞核p27的降解和体外增殖以及{在小鼠EECs中的体内}。重要的是,Skp 2 E3 LIs有可能成为目前通用蛋白酶体抑制剂的主要治疗进展,这些蛋白酶体抑制剂不加选择地阻断蛋白质降解,包括癌基因。Skp 2/Cks 1导致p27降解,而E3连接酶APC/Cdh 1靶向Cks 1/Skp 2进行破坏,使p27保持完整。有趣的是,我们发现E2降低Cdh 1,从而增加Skp 2/Cks 1的p27降解,而Pg和TGF-β 1增加Cdh 1,增加核p27。因此,通过增加Cdh 1或通过阻断Skp 2都可以抑制p27降解。因此,我们将测试两个主要假设:1。Cdh 1-Skp 2/Cks 1-p27轴在泛素蛋白酶体系统(UPS)引起的细胞周期失调中起重要作用; 2. Skp 2 E3 LIs对ECA的治疗具有重要的翻译价值。我们建议:1.使用E2,Pg和TGF-β作为分子开关来了解Cdh 1是如何控制影响p27水平的。2.显示p27和Cdh 1在人类活检组织中的共定位是Pg治疗的阳性结果的生物标志物。{3。对Skp 2-Cks 1-Skp 2 E3 L1复合物进行共结晶/NMR结构分析,以化学优化当前的先导化合物,从而确定p27在体外和体内ECA中的作用。4.通过单细胞成像显微镜定量Skp 2 E3 LI对p27 Skp 2和Cks 1的细胞内[核]运输的影响以及细胞周期分析。5.测试Skp 2 E3 LI在小鼠模型中阻断人ECA肿瘤生长的功效。由于核p27的降解发生在许多癌症中,我们的研究应该通过提供UPS在癌症中的作用以及Skp 2 E3 LIs作为癌症治疗新方法的机制见解来影响癌症生物学领域。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TIMOTHY J CARDOZO其他文献
TIMOTHY J CARDOZO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TIMOTHY J CARDOZO', 18)}}的其他基金
Discovery of novel openers of the understudied human drug target Kir6.1
发现正在研究的人类药物靶标 Kir6.1 的新开启子
- 批准号:
10580933 - 财政年份:2022
- 资助金额:
$ 7.94万 - 项目类别:
ADE-minimized COVID-19 vaccine via epitope focusing and anti-inflammatory innate immunity
通过表位聚焦和抗炎先天免疫实现 ADE 最小化的 COVID-19 疫苗
- 批准号:
10161068 - 财政年份:2020
- 资助金额:
$ 7.94万 - 项目类别:
Epitope optimization for heterologous prime-boost HIV vaccines
异源初免-加强 HIV 疫苗的表位优化
- 批准号:
9138212 - 财政年份:2016
- 资助金额:
$ 7.94万 - 项目类别:
Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancer
稳定核 p27kip1 作为子宫内膜癌的治疗靶点
- 批准号:
8698061 - 财政年份:2014
- 资助金额:
$ 7.94万 - 项目类别:
Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancer
稳定核 p27kip1 作为子宫内膜癌的治疗靶点
- 批准号:
9263411 - 财政年份:2014
- 资助金额:
$ 7.94万 - 项目类别:
Structure Based Characterization of gp120 Non-V3 Variable Loop Epitopes
gp120 非 V3 可变环表位的基于结构的表征
- 批准号:
8733248 - 财政年份:2014
- 资助金额:
$ 7.94万 - 项目类别:
Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancer
稳定核 p27kip1 作为子宫内膜癌的治疗靶点
- 批准号:
9379050 - 财政年份:2014
- 资助金额:
$ 7.94万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 7.94万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 7.94万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 7.94万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 7.94万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 7.94万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 7.94万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 7.94万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 7.94万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 7.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 7.94万 - 项目类别:
Studentship